Barclays sets USD 120 target for Abbott Laboratories stock
Published on 10/13/2026 at 12:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS- Barclays initiated coverage on Abbott Laboratories with an Overweight rating and a USD 120.00 price target on October 7, 2026.
- Second-quarter 2026 revenue reached USD 12.59 billion, up 13.00 percent year over year.
- GAAP diluted earnings per share fell to USD 0.53 as net income declined 47.80 percent in the second quarter.
- Abbott Laboratories stock was trading at EUR 92.27 at Lang & Schwarz on October 13, 2026 at 12:30 p.m. CEST.
Abbott Laboratories (US0028241000) was trading at EUR 92.27 at Lang & Schwarz on October 13, 2026 at 12:30 p.m. CEST. Barclays had initiated coverage on October 7, 2026 with an Overweight rating and a USD 120.00 price target, according to MarketBeat.
Barclays sets a USD 120 target
The October 7, 2026 analyst action gives Abbott a fresh valuation reference ahead of its next quarterly report. MarketBeat said the target implied 22.27 percent upside from the prior US market close, while its cited consensus was Moderate Buy with an average target of USD 118.88.
The rating arrives against a mixed earnings profile. In the second quarter of 2026, Abbott generated USD 12.593 billion in net sales, up 13.00 percent year over year, but GAAP diluted earnings per share fell to USD 0.53 from USD 1.01, according to Ticker Scout.
Three events shape the valuation
On November 19, 2025, Abbott signed the Exact Sciences merger agreement at USD 105.00 in cash per Exact Sciences share. On March 23, 2026, it completed the acquisition, adding cancer diagnostics to its portfolio, according to Ticker Scout.
The latest operating milestone came on July 16, 2026, when second-quarter revenue rose while net income fell to USD 928 million, down 47.80 percent year over year. Acquisition-related intangible amortization, integration expense, higher legal reserves, interest on acquisition debt and a higher tax charge weighed on earnings, while Medical Devices sales increased 9.00 percent to USD 5.853 billion.
What comes next for earnings?
Abbott had reaffirmed full-year 2026 comparable sales growth guidance of 6.50 percent to 7.50 percent and raised adjusted diluted earnings per share guidance to USD 5.45 to USD 5.60 from USD 5.38 to USD 5.58, according to Ticker Scout. That combination of rising sales and lower GAAP profit makes the October report important for testing whether acquisition costs are temporary or remain a drag.
Upcoming reporting dates
Abbott is expected to report third-quarter 2026 results on October 21, 2026, before the US market opens, according to Gekko. Ticker Scout projects the next Form 10-Q filing for October 28, 2026, while identifying the second quarter ended June 30, 2026 as the latest reported period.
Stock trades at Lang & Schwarz
Abbott Laboratories stock was trading at EUR 92.27 at Lang & Schwarz on October 13, 2026 at 12:30 p.m. CEST. The current euro quotation provides the German-market reference ahead of the October reporting date, while the US listing is NYSE: ABT.
The further course of trading is shown by the continuously updated real-time quote of Abbott Laboratories stock.
Abbott Laboratories stock facts
- Company: Abbott Laboratories
- ISIN: US0028241000
- Ticker: ABT
- Primary exchange: NYSE
- Price Lang & Schwarz (as of October 13, 2026, 12:30 p.m. CEST): EUR 92.27
- Market capitalization: USD 169.8 billion (as of October 7, 2026)
- 52-week range: USD 81.97-135.13 (as of October 7, 2026)
- Sector / Industry: Healthcare / Medical devices
- Index membership: S&P 500
- Next earnings date: October 21, 2026
Market context: Market report S&P 500.
